AXSM — Axsome Therapeutics, Inc.

Axsome Therapeutics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $191.2 million, a 57% increase year-over-year, driven primarily by AUVELITY and SUNOSI.
• AUVELITY Revenue: $153.2 million, up 59% year-over-year.
• SUNOSI Revenue: $33.9 million, a 34% increase year-over-year.
• SYMBRAVO Revenue: $4.1 million.
• Net Loss: $64.5 million ($1.26 per share), compared to a net loss of $59.4 million ($1.22 per share) in Q1 2025.
• Cash Position: $305 million at the end of Q1 2026, down from $323 million at year-end 2025.

2. Strategic Updates and Business Highlights

• FDA Approval: AUVELITY received FDA approval for treating agitation associated with Alzheimer's disease, marking a significant expansion of its indications.
• Sales Force Expansion: Increased sales force for AUVELITY to approximately 630 representatives, targeting both community and long-term care settings.
• Market Access Improvements: AUVELITY's commercial coverage is now at 86% of lives across channels, with significant growth in prescribers and demand.
• Pipeline Development: Submitted NDA for AXS-12 for cataplexy in narcolepsy and expanded pipeline with AXS-20 for schizophrenia and Tourette syndrome.
• SYMBRAVO Growth: 36% growth in prescriptions, with new payer contracts securing coverage for approximately 17 million lives.

3. Forward Guidance and Outlook

• Peak Sales Estimates: Updated peak sales potential for AUVELITY to at least $8 billion, with expectations of $4 billion from each indication (MDD and Alzheimer's agitation).
• Revenue Growth: Anticipated continued revenue growth throughout 2026, with expectations for operating leverage as revenue growth outpaces expense growth.
• Clinical Development: Plans to initiate multiple Phase III trials within the next few months for various pipeline candidates.

4. Bad News, Challenges, or Points of Concern

• Net Loss: Despite revenue growth, the company reported a significant net loss, raising concerns about profitability in the near term.
• High SG&A Expenses: Selling, general, and administrative expenses increased to $185 million, driven by prelaunch activities and sales force expansion, potentially impacting cash flow.
• Market Competition: Concerns about competition from emerging therapies, including Orexin-2 receptor agonists for narcolepsy, and the potential impact of new treatment options in the CNS space.

5. Notable Q&A Insights

• Long-Term Care Market: The company is focusing on both community and long-term care facilities for AUVELITY, recognizing the importance of these markets for future growth.
• Sales Force Strategy: Currently, sales representatives are dedicated to specific products, but there may be a shift to promote multiple products as the portfolio expands.
• Pricing Discussions: While engagement with payers is ongoing, specific pricing discussions for AXS-12 have not yet occurred.
• IRA Implications: The impact of the Inflation Reduction Act (IRA) on AUVELITY is not expected until 2031, and the peak sales estimate already accounts for potential IRA effects.
• Interest in Additional Indications: The company is exploring further indications for AUVELITY, leveraging its unique pharmacology and favorable exclusivity runway.

Overall, Axsome Therapeutics demonstrated strong financial growth and strategic advancements in Q1 2026, with significant potential for future revenue driven by its expanding product portfolio and pipeline. However, challenges remain in achieving profitability and navigating competitive pressures in the CNS market.